BRAF V600E

📢 #Thyroid Specialists! 📚 Join us this Friday for the TIRO x MDs Journal Club session featuring @naifa_busaidy as our guest speaker! 🎙️👩‍🔬 She'll be sharing her insights on the use of systemic therapies in BRAF V600E mutated radioactive iodine refractory Thyroid Cancer. 🦋🩺 (@camilo_gzzv)

The BRAF V600E mutation in #coloncancer carries distinct implications and affects 5-15% of cases, leading to a poorer prognosis. Learn about the latest #treatment strategies and expert insights from Dr. Rona Yaeger at #ASCO23. @RonaYaeger https://t.co/Jn6B8zYvYS (@oncologytube)

New treatment in the horizon for patients with +BRAFV600E NSCLC waiting for a new treatment options. Phase II, Open-Label Study of #Encorafenib Plus #Binimetinib in Patients With #BRAFV600 Mutant Metastatic Non–Small-Cell Lung Cancer @RielyMD et al. N=98 💊ORR by IRR was 75%… https://t.co/nxhwhNjnff (@Latinamd)

Dr. @IbiayiMD will discuss #BRAF (both V600E and non) in NSCLC at #DCLung23 on Saturday, October 7, 2023. How should we sequence therapy in this important subtype? New options? Full agenda, faculty and registration at: https://t.co/rJa81GWudC (@StephenVLiu)

📣 #JCO #Editorial: Encorafenib and binimetinib: A new treatment option for BRAF V600E mutant non-small cell ➡️ https://t.co/DHACu5bmdM #LungCancer #LCSM @RielyMD (@JCO_ASCO)

Check out Dr. Vivek Subbiah @VivekSubbiah @SarahCannonDocs discussing #ASCO23 Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors #LCSM #GICSM #BCSM https://t.co/RJQckViT7V (@Sameh_VuMedi)

I have #RET #nsclc. A #RET friend recently progressed on selpercatinib. Biopsy showed #BRAF V600E. Her scans now show tumor reduction & side effects (after need for initial dose reduction) are limited after 2 months on selper + encorafenib. Excited for more articles like these. (@RT_2007)

Case report of a patient with #EGFR mutant NSCLC who developed an acquired #BRAF V600E mutation on osimertinib as well as leptomeningeal disease and achieved durable control with osimertinib, dabrafenib, and trametinib. #JTOCRR @JTOonline https://t.co/TcycKvLI9x (@StephenVLiu)

In Spain we cannot give dabra + trame for BRAF V600E mutant NSCLC, so, imagine for a patient that develop this mutation as a mechanism of resistance to osimertinib 😓 (@BoschBarrera)

Open access article 👉🏼@ASCO educational handbook 2023 - free for all to read👉🏼Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors @JCO_ASCO @ASCOPost @OncoAlert @mgoudaMD https://t.co/qoDkRndgrG (@VivekSubbiah)

Así es. En el caso del #encorafenib para #TratamientoCancerColon con mutación BRAFV600E está financiando en 14 países europeos (🇵🇹🇫🇷🇮🇹🇧🇪...) pero NO en España 👇 https://t.co/b0715ls2dP (@hector_abella)

Had the honor of presenting the NORDIC9 data at the #WCGIC2023. #gerionc @SIOGorg @YoungSIOG @onko_ouh @OncoCareOUH @AgeCare1 @cancer_dk #BRAFV600E (@G_LipositsMD)

Predictive impact of RNF43 mutation in pMMR/MSS BRAFV600E #mCRC treated with target therapy or CTx at #WCGIC2023 👉🎯💊 is effective in all pts, but more effective in mRNF cases 👉We need predictive biomarker -> prospective validation warranted @WCGIC @myESMO @OncoAlert (@ArndtVogel)

? histiocytic sarcoma? CD163, BRAF V600E, IgH PCR (if positive would provide support) (@hemepathguy)

FOLFOXIRI plus Cetuximab or Bevacizumab as 1st-line Treatment of BRAFV600E-mut #coloncancer FIRE-4.5 trial now out in @JCO_ASCO https://t.co/Dme3hX2HeP @StintzingS 👉 if using triplet in mBRAF mCRC, combination with Bev remains the preferable treatment choice @OncoAlert 🚨 (@heinrich_kat)

Yes, but do we need triplet therapy in first line treatment of mBRAF V600E metastatic colorectal cancer? (@DucreuxMichel)

🔥Antitumor Efficacy of Dual Blockade with Encorafenib & Cetuximab with CTx in Human BRAFV600E-mCRC @CCR_AACR https://t.co/PeIO5T2h85 👉interesting preclinical study to evaluate the best combination for targeted and chemotherapies 👇supports BREAKWATER phs-III @myESMO @OncoAlert (@ArndtVogel)

Phase II study of encorafenib + binmetinib in #BRAF V600E NSCLC available @JCO_ASCO. As 1L therapy (n=59), RR 75%, mDOR/PFS not reached, 5m DCR 64%. In later lines (n=39), RR 46%, mDOR 16.7m, mPFS 9.3m, 6m DCR 41%. https://t.co/TQUJpNUhr5 (@StephenVLiu)

Another option looming for #BRAF V600E NSCLC? Congratulations to authors: Drs. @RielyMD @SmitEgbert @EnriquetaFelip @RamalingamMD @AnneTsao2 @MLJohnsonMD2 @NadalErnest @michael_offin @MARIANOPROVENCI et al. With more and more targeted options - remember to test all patients! (@StephenVLiu)

Excited to announce that A022004 randomized trial of adjuvant encorafenib + cetuximab vs usual care after standard rx for BRAF V600E stage III, high risk stage II colon cancer is now activated and available to all NCTN sites. @Alliance_org @EileenMOReilly @smitha42 @SyedKazmiMD (@RonaYaeger)

📣 ASCO 2023 Colon Cancer 📣 ➡️ How does the combination of #Encorafenib and #Cetuximab differ from standard adjuvant therapy for patients with #BRAF V600E mutant #ColorectalCancer? @RonaYaeger @sloan_kettering #ASCO23 🔗 https://t.co/k0buXEgFiW (@oncologytube)

🔥Plasmatic BRAF-V600E allele fraction as a prognostic factor in #colorectalcancer treated with BRAF inhibitors @Annals_Oncology https://t.co/wmEA3KOuZp 👉high BRAF AF: >(liver) mets, worse PFS & OS 👉but may benefit from triplet💊 ✅LB to support💊guidance @myESMO @OncoAlert (@ArndtVogel)

🔥Plasmatic BRAF-V600E allele fraction as a prognostic factor in #colorectalcancer treated with BRAF inhibitors @Annals_Oncology https://t.co/wmEA3KOuZp 👉high BRAF AF: >(liver) mets, worse PFS & OS 👉but may benefit from triplet💊 ✅LB to support💊guidance @myESMO @OncoAlert (@ArndtVogel)

Encorafenib + Binimetinib in BRAF V600E mutant NSCLC shows promising results. Great ORR, significant PFS and probably less toxicity than our current “SoC” with Dabra + Trame. I am such a fan of @RielyMD ;) (@MarceloCorassa)

Our own @RielyMD of @MSKCancerCenter describes the results of a prospective trial of encorafenib and binimetinib for people with RAFV600E-mutant metastatic non-small cell #lungcancer. Read the paper here: https://t.co/Olgqkz01B3 #NSCLC #lcsm #ASCO23 @JCO_ASCO (@MSK_DeptOfMed)

Interesting abstracts re: EGFRi on D3 #ASCO23: FIRE-4, PARADIGM, GOZILA, highlight ctDNA a/w outcome 1. Confirm greatest benefits of EGFRi for L sided KRAS/BRAF V600E wt mCRC 2. Tissue-ctDNA discordance exists. Why 🤔 @StintzingS (@ronanhsieh)

💥 In the context of @ASCO Plenary on brain tumor #ASCO23 👉🏼sharing a major milestone in the #precisionmedicine for BRAF + glioblastoma & the first ever positive targeted therapy for brain tumors. 👉Dabrafenib + trametinib in BRAFV600E-mutant low-grade & high-grade glioma… https://t.co/ZPV7m2CX9Y (@VivekSubbiah)

Lead author @RielyMD of @MSKCancerCenter: "Overall, this shows efficacy for both first-line and second-line use of encorafenib and binimetinib for patients with BRAFV600E-mutant metastatic NSCLC." Read the paper: https://t.co/xR4UeGZhzz #ASCO23 #lcsm (@JCO_ASCO)

Quite an interesting work by @alexdrilon group. SHP2 does not work by itself, but it seems to restore efficacy of TKIs in heavily pretreated patients, including ALK+ NSCLC and BRAF V600E mutant CRC. @GBOT_Alerta #ASCO23 #LCSM (@MarceloCorassa)

Yesterday's sessions are now available on demand🔥Current Immuno-oncology Approaches & the Future for New Combinations in GI Cancers Talk by Dr. Morelli, MD, PhD #ASCO23 #CRCSM @OncoAlert E+C+N trial for BRAFV600E #CRC pts Dr @VanMorrisMD's #SWOG 2107 trial now enrolling. (@manjuggm)

Yesterday's sessions are now available on demand🔥Current Immuno-oncology Approaches & the Future for New Combinations in GI Cancers Talk by Dr. Morelli, MD, PhD #ASCO23 @OncoAlert 😢 LEAP-017 Ph 3 (-) #BRAFV600E:⬆️immunereactive TME? Cell tx+IO? Non-liver met pts did better (@manjuggm)

Thrilled to share our article in the ASCO educational handbook @ASCOPost @ASCO #ASCO23! Don't miss the session today 📚 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors" -->This practical guide… https://t.co/gX38X48QK5 (@VivekSubbiah)

#ASCO23 @ASCO Abs#9018 Encorafenib + binimetinib in #BRAF V600E #NSCLC #PHAROS @RielyMD @RamalingamMD @IbiayiMD @MLJohnsonMD2 @EnriquetaFelip https://t.co/SpYlYRQTL5 @OncoAlert @HemOncToday (@CharuAggarwalMD)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma 3/3 @OncoAlert @weoncologists @Aiims1742 https://t.co/jhdFMv51fX https://t.co/goCcJcP2xH (@VivekSubbiah)

🌟 Feast your eyes on these beautiful figures we created for @VivekSubbiah for the #ASCO23 educational handbook!—FREE access! 📚 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult &Pediatric Solid Tumors"🎯🧬 #DrawImpacts (@DrawImpacts)

🚨Just days before @ASCO 👉🏼 #ASCO23 educational handbook - free open access article is out 👉🏼Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors 🎯🧬 summarizing the latest in BRAF #PrecisionMedicine… https://t.co/70SUhtdj53 (@VivekSubbiah)

WATCH: @skopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E­–mutant metastatic colorectal cancer. #crcsm @MDAndersonNews https://t.co/fs7Xl4BJJA (@OncLive)

🎉 Hot off the press: Our figures now officially published in @ASCOPost educational handbook! Check out @VivekSubbiah & #MohamedGouda's article"Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors"🩺💥 (@DrawImpacts)

Excited to announce the publication of our article in the ASCO educational handbook @ASCOPost @ASCO #ASCO23! 📚 📢 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors" 🩺💥 This practical guide builds… https://t.co/HTPHCkQvOt (@VivekSubbiah)

So many great SWOG trials to let patients know about. SWOG-2107 with Dr. @VanMorrisMD Many, many posts about this trial. So many BRAF V600E MSS crc patients are interested in this trial. https://t.co/oltY9inbWM #swogonc (@fireflyann)

NICE approve 1L Dabrafenib & Trametinib for BRAF V600E NSCLC (@tnewsomdavis)

🔥Encorafenib, Binimetinib & Cetuximab in Previously Untreated BRAF V600E #coloncancer @JCO_ASCO https://t.co/9Ii9etGbte 🔎ANCHOR CRC phs-II 95 pts ✅ORR 47%, mPFS 5.8 mo, mOS 18.3 mo, 60% 2nd line 👉🎯💊feasable in 1st line 👉Binimetenib? CTx? -> BREAKWATER phs-III @myESMO… https://t.co/1vTKv2Bhfk (@ArndtVogel)